Surrozen
Surrozen's revenue fell 67.4% to $4 million in fiscal 2025. Its operating margin was −1,210.6%, down from −239.7% a year earlier. Free cash flow was −$30 million. The diluted share count rose 155.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Surrozen does
Surrozen is a biotechnology company in South San Francisco, California, that develops drugs aimed at the Wnt pathway, a signaling system the body uses to repair and maintain tissue. It has no approved products, so it has no product sales. Its current focus is eye disease. Its lead candidates are antibody-based drugs designed to mimic natural Wnt proteins and boost the pathway.
The company has two lead candidates for retinal diseases. SZN-8141 combines two actions: it activates a receptor called Frizzled 4 and blocks VEGF, a protein involved in abnormal blood vessel growth. It is being developed for diabetic macular edema and wet age-related macular degeneration, and the company expects to submit an application to begin human trials in the second half of 2026. SZN-8143 adds a block on interleukin-6 and is aimed at the same two diseases plus uveitic macular edema. Both have so far been tested in preclinical models. It also has research-stage programs for other eye diseases, including corneal endothelial disease.
Surrozen says it relies on third parties to run its preclinical studies and clinical trials. As of March 1, 2026, it had 44 full-time employees, 27 in research and development and 17 in general and administrative roles.
Its biggest risks, as it describes them
- It has a history of losses and expects more, and may never become profitable.
- It needs substantial additional funds to develop its drug candidates.
- None of its candidates has regulatory approval, and human trials may not show they are safe and effective.
- It may not succeed in using its Wnt platform to build a pipeline of drug candidates.
- It relies on third parties to run its studies and trials, and trials are costly and can be delayed.
Income statement
Surrozen lost money in fiscal 2025: a net loss of $242 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 124 | 76 | 36 | 35 | 89 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 7.8x | 8.3x | 5.8x | 5.3x | 9.2x |
| Quick ratio | 7.8x | 8.3x | 5.8x | 5.3x | 9.2x |
Cash flow
Projections
Project Surrozen's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Surrozen says to expect
- Cash runway: funding of planned studies
The Company anticipates its cash, cash equivalents and marketable securities to provide cash runway into 2029, including funding for completion of the expanded DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b clinical development of SZN-8143.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 5 insiders bought $6.9 million of Surrozen shares on the open market, and 4 insiders sold $7.2 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 22, 2026 | Chen-Ming Yu10% owner | Sold | 325,000 | $21.25 | $6.9 million | Form 4 |
| May 4, 2026 | Craig C ParkerChief Executive Officer, Director | Sold | 4,524 | $33.33 | $150,785 | Form 4 |
| May 4, 2026 | Charles O WilliamsChief Operating Officer | Sold | 2,036 | $33.33 | $67,860 | Form 4 |
| May 4, 2026 | Yang LiExec. Vice President, Research | Sold | 1,584 | $33.33 | $52,795 | Form 4 |
| Mar 24, 2026 | TCG Crossover Fund II L.P.10% owner | Bought | 106,658 | $24.69 | $2.6 million | Form 4 |
| Mar 23, 2026 | TCG Crossover Fund II L.P.10% owner | Bought | 15,223 | $24.90 | $379,053 | Form 4 |
| Mar 16, 2026 | TCG Crossover Fund II L.P.10% owner | Bought | 1,190 | $24.99 | $29,738 | Form 4 |
| Mar 13, 2026 | TCG Crossover Fund II L.P.10% owner | Bought | 35,433 | $24.88 | $881,573 | Form 4 |
| Mar 12, 2026 | TCG Crossover Fund II L.P.10% owner | Bought | 12,374 | $24.99 | $309,226 | Form 4 |
| Feb 12, 2026 | TCG Crossover Fund II L.P.10% owner | Bought | 1,093 | $23.86 | $26,079 | Form 4 |
| Feb 11, 2026 | TCG Crossover Fund II L.P.10% owner | Bought | 17,763 | $23.58 | $418,852 | Form 4 |
| Feb 3, 2026 | TCG Crossover GP III LLC10% owner | Bought | 4,355 | $21.94 | $95,549 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | −940.9% |
| Altman Z'' | −12.63 | −18.77 | −15.54 |
| Accruals ratio | −4.0% | −97.2% | −287.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | — | — | — |
Compare
Put Surrozen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Surrozen | FY25 | −67.4% | −1,210.6% | −873.5% | — | — | — | |
| CRISPR Therapeutics | FY25 | −90.6% | −18,933.7% | −9,855.5% | — | — | — | Compare |
| Dyadic International | FY25 | −11.6% | −232.8% | — | — | — | — | Compare |
| CG Oncology | FY25 | 254.7% | −4,722.1% | −3,279.2% | — | — | 2 | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | 0 | 12 | 0 | 11 | 4 |
| Revenue growth | — | — | — | −100.0% | — | −67.4% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 26 | 40 | 37 | 27 | 21 | 29 |
| Operating income | −33 | −54 | −44 | −46 | −26 | −42 |
| Net income | −33 | −55 | −36 | −43 | −64 | −242 |
| Diluted EPS (US$) | — | −33.15 | −15.56 | −21.33 | −21.67 | −32.37 |
| Diluted shares (millions) | 0 | 2 | 2 | 2 | 3 | 8 |
| Cash flow | ||||||
| Cash from operations | −29 | −49 | −44 | −40 | −18 | −30 |
| Capital expenditure | 1 | 1 | 1 | 0 | 0 | 0 |
| Free cash flow | −30 | −50 | −45 | −41 | −18 | −30 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 3 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 2 | 4 | 4 | 4 | 4 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 49 | 124 | 76 | 36 | 35 | 89 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 62 | 137 | 89 | 46 | 48 | 99 |
| Total liabilities | 15 | 28 | 13 | 8 | 70 | 286 |
| Shareholders' equity | 47 | 110 | 76 | 38 | −21 | −188 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | −354.7% | — | −239.7% | −1,210.6% |
| Net margin | — | — | −288.0% | — | −596.6% | −6,960.8% |
| Free cash flow margin | — | — | −359.0% | — | −165.7% | −873.5% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −940.9% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −69.6% | −38.8% | −75.5% | −767.9% | — |
| Return on assets | — | −54.9% | −31.8% | −63.5% | −134.5% | −328.9% |
| Net debt to EBITDA | — | — | — | — | — | — |